MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4070/kcj.2025.0052

Медицинская библиотека · Korean circulation journal · 2025

Withdrawal of Spironolactone for Heart Failure With Improved Ejection Fraction: An Open-Label, Pilot, Randomized Controlled Trial (With-HF Trial).

Hyun Junho, Lee Seung-Ah, Lee Sang Eun, Hong Jung Ae, Kim Min-Seok, Kim Jae-Joong

СтатьяПеревод в очереди

Аннотация

BACKGROUND AND

OBJECTIVES

The optimal strategy for the maintenance or discontinuation of evidence-based medication is unclear in heart failure (HF) patients with improved left ventricular ejection fraction (LVEF). We tested the feasibility and safety of withdrawing mineralocorticoid receptor antagonists (MRAs) in this population.

METHODS

This is an open-label, prospective, randomized controlled pilot trial including HF patients whose LVEF improved from ≤35% to ≥50% after guideline-directed medical therapy. While testing withdrawal of MRA, other medications were maintained. The primary endpoint was the proportion of patients showing deteriorations in LVEF by ≥10% at 6-month follow-up. The secondary endpoints were numerical changes in echocardiographic parameters, changes in blood natriuretic peptide levels, and adverse clinical events relevant to HF.

RESULTS

We randomly assigned 62 HF patients with improved LVEF to the withdrawal or continuation groups. Two (6.7%) patients in the withdrawal group and one (3.2%) patient in the continuation group showed deterioration in LVEF by ≥10% at 6 months; one of the 2 patients in the withdrawal group who showed a decline in LVEF had LVEF of less than 50% at follow-up. Re-initiation of MRA did not occur in any patients. Compared with baseline, echocardiographic parameters, including LV end-diastolic volume index, global longitudinal strain, and natriuretic peptides, were similar at follow-up in both groups.

CONCLUSIONS

MRA withdrawal was associated with a low risk of significant deterioration of cardiac function in HF patients with improved LVEF of ≥50%. MRA withdrawal may be feasible and safe in this population.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04367051.

Для цитирования: Hyun Junho, Lee Seung-Ah, Lee Sang Eun, Hong Jung Ae, Kim Min-Seok, Kim Jae-Joong. Withdrawal of Spironolactone for Heart Failure With Improved Ejection Fraction: An Open-Label, Pilot, Randomized Controlled Trial (With-HF Trial).. Korean circulation journal. 2025. DOI: 10.4070/kcj.2025.0052.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.